Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pasithea Therapeutics Corp. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and warrants. The company’s 8-K reports cover executive appointments, Regulation FD communications, shareholder voting matters, equity incentive plan approvals, Nasdaq continued-listing compliance and other material events.
Pasithea’s registration statements describe securities offerings, capital structure, emerging growth company status and risk disclosures related to biotechnology research and development. Its filings also identify the company’s Delaware incorporation, Miami Beach executive office, common stock under KTTA and warrants under KTTAW.
Pasithea Therapeutics Corp. filed an initial Form 3 for Kartik Krishnan, who serves as Chief Medical Officer. The filing establishes his status as an officer and a reportable insider of the company but does not list any share holdings or recent transactions.
Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026. He will lead clinical development and medical strategy as the company advances its PAS-004 MEK inhibitor program in neurofibromatosis type 1 and other indications.
Under an Executive Employment Agreement dated April 3, 2026, Dr. Krishnan receives an initial $500,000 base salary and is eligible for an annual discretionary bonus of up to 40% of salary, plus participation in benefit plans. On May 1, 2026, the board granted him options to purchase 1,129,323 shares at an exercise price of $0.841 per share, alongside sizable option grants to the CEO, CFO, other employees and non‑employee directors, with multi‑year vesting and full vesting upon a Change in Control.
Pasithea Therapeutics Corp. ownership disclosure: institutional holder Funicular Funds, LP (and related entities Cable Car Capital, LP and Jacob Ma-Weaver) reports beneficial ownership of 1,839,512 shares of Common Stock, representing 7.4% of the class based on 24,939,948 shares outstanding as reported on the issuer's Form 10-K filed March 30, 2026.
The filing lists sole voting and dispositive power for each reporting person over the same 1,839,512 shares and discloses the reporting relationships between Funicular Funds, Cable Car Capital, LP, and Jacob Ma-Weaver.
Coastlands Capital LP, as a 10% owner of Pasithea Therapeutics Corp., reported its initial holdings. It indirectly holds Pre-Funded Warrants exercisable into 11,233,334 shares of common stock at an exercise price of $0.001 per share, with no expiration date.
Coastlands also indirectly holds 3,735,035 shares of Pasithea common stock. The Pre-Funded Warrants are exercisable at any time after issuance but include a 9.99% beneficial ownership cap, limiting exercises that would push ownership above that threshold. The reporting persons jointly file and disclaim beneficial ownership beyond their pecuniary interest.
Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of 2,491,000 shares of Pasithea Therapeutics Corp. common stock (CUSIP 70261F202), representing 9.99% of the class. The filing states shared voting and dispositive power over the 2,491,000 shares held directly by the Fund. The filing cites 24,939,948 common shares outstanding as of 03/24/2026 per Pasithea's Form 10-K. The joint statement is signed by James Silverman with signature dates of 04/08/2026.
Pasithea Therapeutics Corp. files its 2025 annual report as a clinical-stage biotech focused on PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor targeting RASopathies, MAPK-driven tumors and NF1-related tumors. The company is running two global Phase 1 programs in advanced cancers and adult NF1 plexiform neurofibromas.
Interim data from the advanced cancer study show no dose-limiting toxicities through eight dose-escalation cohorts and a tolerability profile limited to grade 1–2 treatment-related events, with a PAS-004 half-life of about 60 hours and low peak-to-trough variability. Pasithea also advances discovery program PAS-001 for schizophrenia targeting complement component 4A.
As of June 30, 2025, non-affiliate common stock held a market value of $5.1 million. As of March 24, 2026, there were 24,939,948 common shares outstanding, alongside 64,053,335 pre-funded warrants immediately exercisable at $0.001 per share, subject to beneficial ownership limits.
Pasithea Therapeutics Corp. reports Coastlands-affiliated filers hold 2,394,765 shares, representing 9.99% of common stock. The reported position consists of 1,514,199 shares held directly and 880,566 shares issuable upon exercise of pre-funded warrants, calculated using 23,091,062 shares outstanding as of December 22, 2025. The filing shows shared voting and dispositive power over the 2,394,765 shares and states the 9.99% beneficial ownership limitation applies to the warrants.
The filing is submitted jointly by Coastlands Capital entities and Matthew D. Perry, who is identified as a control person; each reporting person disclaims membership in a group and disclaims beneficial ownership except to the extent of pecuniary interest.
Pasithea Therapeutics Corp. received a notice from Nasdaq on February 20, 2026 stating that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The company has 180 calendar days, until August 19, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least ten consecutive business days. If it meets other listing standards, it may qualify for an additional 180-day period and could use actions such as a reverse stock split to cure the deficiency.
If compliance is not regained, Nasdaq staff may move to delist the shares, though the company would have the right to appeal. The company plans to monitor its share price and evaluate options, and states that this notice does not affect its business operations or SEC reporting.
Pasithea Therapeutics Corp. received an updated ownership report from institutional investors CVI Investments, Inc. and Heights Capital Management, Inc. The Reporting Persons state beneficial ownership of 899,994 shares of Pasithea common stock, representing 3.8% of the outstanding shares as of the referenced date.
The position consists of shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired at any time. Pasithea’s definitive proxy indicates 23,091,062 shares of common stock were outstanding as of December 22, 2025, providing context for the reported 3.8% stake.
CVI Investments, Inc. is organized in the Cayman Islands and Heights Capital Management, Inc. in Delaware. Heights acts as investment manager to CVI and may exercise voting and dispositive power over the reported shares, while both parties disclaim beneficial ownership beyond their economic interest.
Pasithea Therapeutics Corp. reported ownership update from Squadron entities. Squadron Master Fund LP, its adviser Squadron Capital Management LLC, and principals Matthew Sesterhenn and William Blank report beneficial ownership of 2,329,749 shares of Pasithea common stock, including 2,100,000 shares and 229,749 shares issuable upon exercise of warrants.
These holdings represent approximately 9.99% of Pasithea’s common stock, based on 23,091,062 shares outstanding as of December 22, 2025 plus the warrant shares. The reporting persons share voting and dispositive power over all reported shares, state that the position is held in the ordinary course of business, and expressly disclaim beneficial ownership beyond what may be imputed under SEC rules.